PABPC1 and central nervous system cancer: Among them, the mice carrying the combined treatment produced the significantly smallest tumors and had the highest survival, suggesting that the combination of PABPC1 overexpression and BDNF-AS overexpression could be potentially applied in the treatment of glioma.